
Arovella Therapeutics Ltd
ASX:ALA

Intrinsic Value
The intrinsic value of one
ALA
stock under the Base Case scenario is
0.006
AUD.
Compared to the current market price of 0.088 AUD,
Arovella Therapeutics Ltd
is
Overvalued by 93%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Arovella Therapeutics Ltd
Fundamental Analysis
Want a deep‑dive on Arovella Therapeutics Ltd?
Request it below and we’ll move it up the queue.

Revenue & Expenses Breakdown
Arovella Therapeutics Ltd
Balance Sheet Decomposition
Arovella Therapeutics Ltd
Current Assets | 12.2m |
Cash & Short-Term Investments | 11.8m |
Other Current Assets | 455.3k |
Non-Current Assets | 441.3k |
PP&E | 441.3k |
Free Cash Flow Analysis
Arovella Therapeutics Ltd
AUD | |
Free Cash Flow | AUD |
Earnings Waterfall
Arovella Therapeutics Ltd
Revenue
|
442.1k
AUD
|
Operating Expenses
|
-6.7m
AUD
|
Operating Income
|
-6.3m
AUD
|
Other Expenses
|
0
AUD
|
Net Income
|
-6.3m
AUD
|
ALA Profitability Score
Profitability Due Diligence
Arovella Therapeutics Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Score
Arovella Therapeutics Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
ALA Solvency Score
Solvency Due Diligence
Arovella Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Arovella Therapeutics Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALA Price Targets Summary
Arovella Therapeutics Ltd
Dividends
Current shareholder yield for ALA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ALA
stock under the Base Case scenario is
0.006
AUD.
Compared to the current market price of 0.088 AUD,
Arovella Therapeutics Ltd
is
Overvalued by 93%.